Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers
07/2020
Journal Article
Authors:
Lin, L. L.;
Lakomy, D. S.;
Chiao, E. Y.;
Strother, R. M.;
Wirth, M.;
Cesarman, E.;
Borok, M.;
Busakhala, N.;
Chibwesha, C. J.;
Chinula, L.;
Ndlovu, N.;
Orem, J.;
Phipps, W.;
Sewram, V.;
Vogt, S. L.;
Sparano, J. A.;
Mitsuyasu, R. T.;
Krown, S. E.;
Gopal, S.
Volume:
6
Pagination:
1134-1146
Journal:
JCO Glob Oncol
PMID:
32697667
URL:
https://www.ncbi.nlm.nih.gov/pubmed/32697667
Keywords:
Africa South of the Sahara/epidemiology
Capacity Building
Female
*HIV Infections/epidemiology/prevention & control
Humans
*Neoplasms/epidemiology/prevention & control
*Sarcoma, Kaposi
Abstract:
PURPOSE: The aim of this study was to review the current status of clinical trials for HIV-associated malignancies in people living with HIV in sub-Saharan Africa (SSA) and efforts made by the AIDS Malignancy Consortium (AMC) to build capacity in SSA for HIV malignancy research. METHODS: All malignancy-related clinical trials in 49 SSA countries on ClinicalTrials.gov were reviewed and evaluated for inclusion and exclusion criteria pertaining to HIV status. Additional studies by AMC in SSA were compiled from Web-based resources, and narrative summaries were prepared to highlight AMC capacity building and training initiatives. RESULTS: Of 96 cancer trials identified in SSA, only 11 focused specifically on people living with HIV, including studies in Kaposi sarcoma, cervical dysplasia and cancer, non-Hodgkin lymphoma, and ocular surface squamous neoplasia. Recognizing the increasing cancer burden in the region, AMC expanded its clinical trial activities to SSA in 2010, with 4 trials completed to date and 6 others in progress or development, and has made ongoing investments in developing research infrastructure in the region. CONCLUSION: As the HIV-associated malignancy burden in SSA evolves, research into this domain has been limited. AMC, the only global HIV malignancy-focused research consortium, not only conducts vital HIV-associated malignancies research in SSA, but also develops pathology, personnel, and community-based infrastructure to meet these challenges in SSA. Nonetheless, there is an ongoing need to build on these efforts to improve HIV-associated malignancies outcomes in SSA.
